ArticleInternational journal of cancer2021
Differences in risk factors for molecular subtypes of clear cell renal cell carcinoma.
Article in International journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Oxalate induces proliferation and mitochondrial metabolism in select clear cell renal cell carcinoma cell lines.BMC cancer · 2026Article
- Enhanced expression of CXCL1 in renal cell carcinoma facilitates tumor cell malignancy via PI3K/AKT-dependent mechanisms.Oncology letters · 2026Article
- Using Mendelian randomization to investigate etiologic heterogeneity across renal cell carcinoma subtypes.International journal of epidemiology · 2025Article
- Emerging Biomarkers in Urological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling.International journal of molecular sciences · 2025Review
- SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers.Nature communications · 2025Article
- Pre- and post-diagnosis body weight trajectories in patients with localized renal cell cancer.Cancer causes & control : CCC · 2025Article
- Feature graphs for interpretable unsupervised tree ensembles: centrality, interaction, and application in disease subtyping.BioData mining · 2025Article
- BBOX1 restrains TBK1-mTORC1 oncogenic signaling in clear cell renal cell carcinoma.Nature communications · 2025Article
- ACE Loss Drives Renal Cell Carcinoma Growth and Invasion by Modulating AKT-FOXO1.Biologics : targets & therapy · 2024Article
- Molecular differences in renal cell carcinoma between males and females.World journal of urology · 2023Review
- Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients.Cancer medicine · 2023Article
- A comparison of analytic approaches for investigating the obesity paradox in kidney cancer.Cancer causes & control : CCC · 2023Article
- Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments.JCO precision oncology · 2023Review
- Article
- Lactate metabolism orchestrates immune dysregulation in renal cancer: A multi-omics and causal inference study.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 6 countries.
Funding
Abstract
The ccA and ccB molecular subtypes of clear cell renal cell carcinoma (ccRCC) have well-characterized prognostic relevance. However, it is not known whether they possess distinct etiologies. We investigated the relationships between these subtypes and RCC risk factors within a case-control study conducted in Eastern Europe. We analyzed risk factor data for ccA (n = 144) and ccB (n = 106) cases and 1476 controls through case-only and case-control comparisons to assess risk factor differences across subtypes using logistic and polytomous regression models. We also performed a meta-analysis summarizing case-only results from our study and three patient cohorts. Patients with ccB tumors had poorer survival than those with ccA tumors and were more likely to be male (case-only odds ratio [OR] 2.68, 95% confidence interval [CI] 1.43-5.03). In case-control analyses, body mass index was significantly associated with ccA tumors (OR 2.45, 95% CI 1.18-5.10 for ≥35 vs <25 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.